A Serine Palmitoyltransferase Inhibitor Blocks Hepatitis C Virus Replication in Human Hepatocytes

• Published in: Gastroenterology (New York, N.Y. 1943) Vol. 145; no. 4; pp. 865 - 873
• Main Authors: Katsume, Asao, Tokunaga, Yuko, Hirata, Yuichi, Munakata, Tsubasa, Saito, Makoto, Hayashi, Hitohisa, Okamoto, Koichi, Ohmori, Yusuke, Kusanagi, Isamu, Fujiwara, Shinya, Tsukuda, Takuo, Aoki, Yuko, Klumpp, Klaus, Tsukiyama–Kohara, Kyoko, El–Gohary, Ahmed, Sudoh, Masayuki, Kohara, Michinori
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2013
• Subjects: Animals; Antiviral Agents - pharmacology; DAAs; Direct-Acting Antiviral Agents; Drug; Gastroenterology and Hepatology; HCV Lifecycle; Hepacivirus - classification; Hepacivirus - drug effects; Hepacivirus - genetics; Hepatocytes - virology; Humans; Mice; RNA, Viral - analysis; Serine C-Palmitoyltransferase - antagonists & inhibitors; Virus Replication - drug effects; DAAs; Drug; HCV Lifecycle; Direct-Acting Antiviral Agents; DAA; SPT; IC50; RBV; PEG-IFN; cDNA; HCV; PCR; 50% inhibitory concentration; IC 50; pegylated interferon alfa-2a; ribavirin; serine palmitoyltransferase; complementary DNA; direct-acting antiviral agent; hepatitis C virus; polymerase chain reaction; IC
• ISSN: 0016-5085; 1528-0012; 1528-0012
• DOI: 10.1053/j.gastro.2013.06.012

Host cell lipid rafts form a scaffold required for replication of hepatitis C virus (HCV). Serine palmitoyltransferases (SPTs) produce sphingolipids, which are essential components of the lipid rafts that associate with HCV nonstructural proteins. Prevention of the de novo synthesis of sphingolipids by an SPT inhibitor disrupts the HCV replication complex and thereby inhibits HCV replication. We investigated the ability of the SPT inhibitor NA808 to prevent HCV replication in cells and mice. We tested the ability of NA808 to inhibit SPT’s enzymatic activity in FLR3-1 replicon cells. We used a replicon system to select for HCV variants that became resistant to NA808 at concentrations 4- to 6-fold the 50% inhibitory concentration, after 14 rounds of cell passage. We assessed the ability of NA808 or telaprevir to inhibit replication of HCV genotypes 1a, 1b, 2a, 3a, and 4a in mice with humanized livers (transplanted with human hepatocytes). NA808 was injected intravenously, with or without pegylated interferon alfa-2a and HCV polymerase and/or protease inhibitors. NA808 prevented HCV replication via noncompetitive inhibition of SPT; no resistance mutations developed. NA808 prevented replication of all HCV genotypes tested in mice with humanized livers. Intravenous NA808 significantly reduced viral load in the mice and had synergistic effects with pegylated interferon alfa-2a and HCV polymerase and protease inhibitors. The SPT inhibitor NA808 prevents replication of HCV genotypes 1a, 1b, 2a, 3a, and 4a in cultured hepatocytes and in mice with humanized livers. It might be developed for treatment of HCV infection or used in combination with pegylated interferon alfa-2a or HCV polymerase or protease inhibitors.